167 related articles for article (PubMed ID: 28453754)
1. Once- Versus Twice-daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial.
Turner D; Yerushalmi B; Kori M; Broide E; Mozer-Glassberg Y; Shaoul R; Kolho KL; Shteyer E; Shamaly H; Ledder O; Cohen S; Peleg S; On A; Levine A
J Crohns Colitis; 2017 May; 11(5):527-533. PubMed ID: 28453754
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of once daily versus twice daily mesalazine for mild-to-moderate ulcerative colitis: A meta-analysis of randomized controlled trials.
Zheng X; Zhang Z; Wang B; Li J; Qiu C; Zhang Q; Wang X
Medicine (Baltimore); 2019 Apr; 98(14):e15113. PubMed ID: 30946380
[TBL] [Abstract][Full Text] [Related]
3. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial.
Kruis W; Kiudelis G; Rácz I; Gorelov IA; Pokrotnieks J; Horynski M; Batovsky M; Kykal J; Boehm S; Greinwald R; Mueller R;
Gut; 2009 Feb; 58(2):233-40. PubMed ID: 18832520
[TBL] [Abstract][Full Text] [Related]
4. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.
Flourié B; Hagège H; Tucat G; Maetz D; Hébuterne X; Kuyvenhoven JP; Tan TG; Pierik MJ; Masclee AA; Dewit O; Probert CS; Aoucheta D;
Aliment Pharmacol Ther; 2013 Apr; 37(8):767-75. PubMed ID: 23451806
[TBL] [Abstract][Full Text] [Related]
5. Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4 g or twice-daily 2g mesalazine dosing.
Connolly MP; Kuyvenhoven JP; Postma MJ; Nielsen SK
J Crohns Colitis; 2014 May; 8(5):357-62. PubMed ID: 24094599
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study.
Hyams JS; Davis S; Mack DR; Boyle B; Griffiths AM; LeLeiko NS; Sauer CG; Keljo DJ; Markowitz J; Baker SS; Rosh J; Baldassano RN; Patel A; Pfefferkorn M; Otley A; Heyman M; Noe J; Oliva-Hemker M; Rufo P; Strople J; Ziring D; Guthery SL; Sudel B; Benkov K; Wali P; Moulton D; Evans J; Kappelman MD; Marquis A; Sylvester FA; Collins MH; Venkateswaran S; Dubinsky M; Tangpricha V; Spada KL; Britt A; Saul B; Gotman N; Wang J; Serrano J; Kugathasan S; Walters T; Denson LA
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):855-868. PubMed ID: 28939374
[TBL] [Abstract][Full Text] [Related]
7. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis.
Kamm MA; Lichtenstein GR; Sandborn WJ; Schreiber S; Lees K; Barrett K; Joseph R
Gut; 2008 Jul; 57(7):893-902. PubMed ID: 18272546
[TBL] [Abstract][Full Text] [Related]
8. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Murray A; Nguyen TM; Parker CE; Feagan BG; MacDonald JK
Cochrane Database Syst Rev; 2020 Aug; 8(8):CD000544. PubMed ID: 32856298
[TBL] [Abstract][Full Text] [Related]
9. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000544. PubMed ID: 23076890
[TBL] [Abstract][Full Text] [Related]
10. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Wang Y; Parker CE; Feagan BG; MacDonald JK
Cochrane Database Syst Rev; 2016 May; 2016(5):CD000544. PubMed ID: 27158764
[TBL] [Abstract][Full Text] [Related]
11. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Wang Y; Parker CE; Bhanji T; Feagan BG; MacDonald JK
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD000543. PubMed ID: 27101467
[TBL] [Abstract][Full Text] [Related]
12. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
[TBL] [Abstract][Full Text] [Related]
13. 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial.
Gross V; Bunganic I; Belousova EA; Mikhailova TL; Kupcinskas L; Kiudelis G; Tulassay Z; Gabalec L; Dorofeyev AE; Derova J; Dilger K; Greinwald R; Mueller R;
J Crohns Colitis; 2011 Apr; 5(2):129-38. PubMed ID: 21453882
[TBL] [Abstract][Full Text] [Related]
14. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Murray A; Nguyen TM; Parker CE; Feagan BG; MacDonald JK
Cochrane Database Syst Rev; 2020 Aug; 8(8):CD000543. PubMed ID: 32786164
[TBL] [Abstract][Full Text] [Related]
15. Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing.
Bokemeyer B; Hommes D; Gill I; Broberg P; Dignass A
J Crohns Colitis; 2012 May; 6(4):476-82. PubMed ID: 22398060
[TBL] [Abstract][Full Text] [Related]
16. Mesalamine Enemas for Induction of Remission in Oral Mesalamine-refractory Pediatric Ulcerative Colitis: A Prospective Cohort Study.
Levine A; Yerushalmi B; Kori M; Broide E; Mozer-Glassberg Y; Shaoul R; Kolho KL; Shteyer E; Shamaly H; Ledder O; Cohen S; Peleg S; Shabat CS; Focht G; Shachmon E; Boaz M; On A; Turner D
J Crohns Colitis; 2017 Aug; 11(8):970-974. PubMed ID: 28369299
[TBL] [Abstract][Full Text] [Related]
17. Once daily vs multiple daily mesalamine therapy for mild to moderate ulcerative colitis: a meta-analysis.
Li W; Zhang ZM; Jiang XL
Colorectal Dis; 2016 Jul; 18(7):O214-23. PubMed ID: 27214762
[TBL] [Abstract][Full Text] [Related]
18. Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis.
D'Haens GR; Sandborn WJ; Zou G; Stitt LW; Rutgeerts PJ; Gilgen D; Jairath V; Hindryckx P; Shackelton LM; Vandervoort MK; Parker CE; Muller C; Pai RK; Levchenko O; Marakhouski Y; Horynski M; Mikhailova E; Kharchenko N; Pimanov S; Feagan BG
Aliment Pharmacol Ther; 2017 Aug; 46(3):292-302. PubMed ID: 28568974
[TBL] [Abstract][Full Text] [Related]
19. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
Kruis W; Schreiber S; Theuer D; Brandes JW; Schütz E; Howaldt S; Krakamp B; Hämling J; Mönnikes H; Koop I; Stolte M; Pallant D; Ewald U
Gut; 2001 Dec; 49(6):783-9. PubMed ID: 11709512
[TBL] [Abstract][Full Text] [Related]
20. One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis.
Hawthorne AB; Stenson R; Gillespie D; Swarbrick ET; Dhar A; Kapur KC; Hood K; Probert CS
Inflamm Bowel Dis; 2012 Oct; 18(10):1885-93. PubMed ID: 22081522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
